SPIA
KLRS

Steward Partners Investment Advisory’s Kalaris Therapeutics KLRS Stock Holding History

Steward Partners Investment Advisory’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.02K Hold
2,215
– – ﹤0.01% 3776
2026
Q1 		$12.8K Buy
+2,215
New +$19.7K ﹤0.01% 3449

Other funds holding KLRS

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
WT
WHI Trust Chicago, Illinois $155M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Steward Partners Investment Advisory's KLRS Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 2,215 shares worth $9.02K. The position accounts for ﹤0.01% of the portfolio, ranked #3776.

Steward Partners Investment Advisory first reported a position in KLRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.8K in Q1 2026. 48 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Steward Partners Investment Advisory held 2,215 shares of Kalaris Therapeutics worth $9.02K as of Q2 2026.
  • Steward Partners Investment Advisory left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3776 holding.
  • Steward Partners Investment Advisory first reported a position in Kalaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Steward Partners Investment Advisory's Kalaris Therapeutics position peaked at $12.8K in Q1 2026.
  • 48 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.